@ eligible patients ( aged @ years ) with homozygous familial hypercholesterolaemia , on stable lipid-regulating therapy for at least @ weeks , and not receiving lipoprotein apheresis , were randomly allocated by a computer-generated randomisation sequence in a @:@ ratio to receive subcutaneous evolocumab @ mg or placebo every @ weeks for @ weeks .